Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...